NCT05487053 The Impact of Single-shot Adductor Canal Block Versus Continuous Femoral Nerve Block on Rehabilitation After Total Knee Replacement
| NCT ID | NCT05487053 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Negovsky Reanimatology Research Institute |
| Condition | Osteo Arthritis Knee |
| Study Type | INTERVENTIONAL |
| Enrollment | 220 participants |
| Start Date | 2024-02-03 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 220 participants in total. It began in 2024-02-03 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Total knee replacement (TKR) is considered the most effective and safe method of radical treatment of late stages of knee osteoarthritis. A well-known problem of TKR is a severe postoperative pain syndrome, which is observed in more than 50% of patients. Femoral nerve block (FNB) is the "gold standard" for continuous postoperative analgesia after total knee replacement, as it is effective in reducing the frequency of use of opioid analgetics and reduce the duration of hospitalization. At the same time, the negative effect of this method is the motor blockade of the quadriceps femoris muscle which leads to functional impairment and is associated with an increased risk of falling. Adductor canal block (ACB) provides adequate analgesia comparable to femoral nerve block. Moreover, ACB doesn't affect the motor function of the quadriceps femoris muscle. The possibility of enhanced recovery after total knee replacement is the reason to compare single-shot adductor canal block and continuous femoral nerve block.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 * Planned primary total knee replacement * Planned neuraxial anesthesia * Written informed consent Exclusion Criteria: * Urgent surgery * Planned revision total knee replacement * Known allergic reaction to anesthetics * Confirmed localized infection at the puncture sites * Confirmed localized tumor at the puncture sites * Peripheral neuropathy of the lower extremities * Parkinson's disease * Previously enrolled in this trial
Contact & Investigator
Valery Likhvantsev
PRINCIPAL INVESTIGATOR
Negovsky Reanimatology Research Institute
Frequently Asked Questions
Who can join the NCT05487053 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Osteo Arthritis Knee. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05487053 currently recruiting?
Yes, NCT05487053 is actively recruiting participants. Contact the research team at lik0704@gmail.com for enrollment information.
Where is the NCT05487053 trial being conducted?
This trial is being conducted at Moscow, Russia.
Who is sponsoring the NCT05487053 clinical trial?
NCT05487053 is sponsored by Negovsky Reanimatology Research Institute. The principal investigator is Valery Likhvantsev at Negovsky Reanimatology Research Institute. The trial plans to enroll 220 participants.